Oral Biologics Market, By Drug Class (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, and Others), By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bow

Oral Biologics Market, By Drug Class (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, and Others), By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC), and Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn’s disease, and ulcerative colitis.
Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parenteral route and only guanylate cyclase-c agonist class of drug is approved oral biologics in market.
However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.
Market Dynamics
Increasing number of inorganic strategies such as collaborations, partnerships, mergers, and acquisition by key players is a major factor driving growth of the market. For instance, in February 2021, Biocon Limited announced merger with International Diabetes Federation (IDF), an insulin biosimilar company, and the merger focuses on the research and development of Biocon’s biologics segment and promote the affordable access of insulin products manufactured by Biocon to the diabetes patients globally.
Key features of the study:
This report provides in-depth analysis of the global oral biologics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global oral biologics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral biologics market
Detailed Segmentation:
Global Oral Biologics Market, By Drug Class:
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
Hormone
Recombinant Enzyme
Guanylate Cyclase-C Agonist
Somatostatin Analogue
Others
Global Oral Biologics Market, By Disease Indication:
Diabetes
Hyperoxaluria
Acromegaly
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
Global Oral Biologics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Oral Biologics Market, By Region:
North America
By Drug Class
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
Hormone
Recombinant Enzyme
Guanylate Cyclase-C Agonist
Somatostatin Analogue
Others
By Disease Indication
Diabetes
Hyperoxaluria
Acromegaly
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Class
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
Hormone
Recombinant Enzyme
Guanylate Cyclase-C Agonist
Somatostatin Analogue
Others
By Disease Indication
Diabetes
Hyperoxaluria
Acromegaly
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
Hormone
Recombinant Enzyme
Guanylate Cyclase-C Agonist
Somatostatin Analogue
Others
By Disease Indication
Diabetes
Hyperoxaluria
Acromegaly
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
Hormone
Recombinant Enzyme
Guanylate Cyclase-C Agonist
Somatostatin Analogue
Others
By Disease Indication
Diabetes
Hyperoxaluria
Acromegaly
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
Hormone
Recombinant Enzyme
Guanylate Cyclase-C Agonist
Somatostatin Analogue
Others
By Disease Indication
Diabetes
Hyperoxaluria
Acromegaly
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Class
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
Hormone
Recombinant Enzyme
Guanylate Cyclase-C Agonist
Somatostatin Analogue
Others
By Disease Indication
Diabetes
Hyperoxaluria
Acromegaly
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
South Africa
Central Africa
North Africa
Company Profiles
Novo Nordisk A/S *
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Biocon Limited
Oramed Pharmaceuticals, Inc.
Rani Therapeutics
Entera Bio Ltd.
AbbVie Inc.
Enteris BioPharma, Inc.
Chiasma, Inc.
Allena Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.